![conference banner](/images/conference-banner.jpeg)
Abstract
Venous thromboembolism is a common condition and low molecular weight heparins (LMWHs) are widely used for its treatment. Chronic kidney disease (CKD) is also a frequent disease especially in subjects with comorbidities admitted to internal medicine wards. LMWHs are eliminated by the kidney and their half-life is increased in renal impairment. Based on a series of available studies we analyzed the relationship between treatment with LMWHs and different degrees of renal impairment including end-stage renal disease (ESRD). In order to reduce haemorrhagic risk, the LMWH dose should be reduced in CKD, even if reducing LMWH dose could impair drug effectiveness. Further studies relating glomerular filtration rate to LMWH effectiveness and side effects are required.
Keywords: Low molecular heparin, chronic kidney disease, dialysis, glomerular filtration rate, thromboembolism, acute coronary syndrome, atrial fibrillation, ischaemic stroke, cardiomyopathy, plasminogen activator inhibitor type 1
Current Vascular Pharmacology
Title: Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Volume: 9 Issue: 6
Author(s): Fabio Fabbian, Alfredo De Giorgi, Marco Pala, Ruana Tiseo, Francesco Portaluppi, Davide Imberti and Roberto Manfredini
Affiliation:
Keywords: Low molecular heparin, chronic kidney disease, dialysis, glomerular filtration rate, thromboembolism, acute coronary syndrome, atrial fibrillation, ischaemic stroke, cardiomyopathy, plasminogen activator inhibitor type 1
Abstract: Venous thromboembolism is a common condition and low molecular weight heparins (LMWHs) are widely used for its treatment. Chronic kidney disease (CKD) is also a frequent disease especially in subjects with comorbidities admitted to internal medicine wards. LMWHs are eliminated by the kidney and their half-life is increased in renal impairment. Based on a series of available studies we analyzed the relationship between treatment with LMWHs and different degrees of renal impairment including end-stage renal disease (ESRD). In order to reduce haemorrhagic risk, the LMWH dose should be reduced in CKD, even if reducing LMWH dose could impair drug effectiveness. Further studies relating glomerular filtration rate to LMWH effectiveness and side effects are required.
Export Options
About this article
Cite this article as:
Fabbian Fabio, De Giorgi Alfredo, Pala Marco, Tiseo Ruana, Portaluppi Francesco, Imberti Davide and Manfredini Roberto, Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered, Current Vascular Pharmacology 2011; 9 (6) . https://dx.doi.org/10.2174/157016111797484170
DOI https://dx.doi.org/10.2174/157016111797484170 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Cardiotonics: Search and Problems
Cardiovascular & Hematological Disorders-Drug Targets Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Cardiovascular & Hematological Disorders-Drug Targets Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery The Cardiac Conduction and Contractility Complications of Methamphetamine Use and the Relationship to Psychiatric Comorbidity: A Systematic Review
Current Psychiatry Research and Reviews MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Novel Therapeutic Options for Chagas Disease Based on Bioactive Compounds from Algae, Bacteria and Fungi Species
Current Medicinal Chemistry An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Heart Failure in East Asia
Current Cardiology Reviews Nrf2 Mediates Effect of Resveratrol in Ischemia-reperfusion Injury
Current Molecular Pharmacology